Building upon these results, it would be valuable to investigate miR-129-5p levels using qPCR in blood samples obtained from both pre-symptomatic and symptomatic FTD patients carrying C9ORF72, GRN, and MAPT mutations. The gene discussed is MAPT; the disease is frontotemporal dementia.